• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Switzerland·Financial Services·HBMN.SW
Share

HBM Healthcare Investments AG Ord Stocks

CHF 249.5Last Updated 10.07.2026

Issuer Rating

6/7
Performance

Average

Risk

Low

Recommendation

Buy

Market Cap

CHF 2.04B

CHF 249.5
Key Takeaways

Risk factor

Low price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Solid dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

HBM Healthcare Investments AG specializes in both direct investments and a fund-of-funds strategy, focusing exclusively on the healthcare sector, encompassing human medicine, pharmaceuticals, biotechnology, diagnostics, and medical technology. Its direct investments target a diverse range of companies, from early-stage startups and various venture and growth phases to mature private enterprises, unlisted emerging firms, and small-cap public entities. The firm also provides capital for company buyouts, growth initiatives, Private Investments in Public Equity (PIPEs), and the spin-off of product lines or departments from larger corporations, as well as the expansion or restructuring of established businesses. Through its fund-of-funds approach, HBM allocates capital to venture capital funds. Initial direct investments are typically made in companies whose primary products are either in clinical development or just prior to that stage. With a global investment mandate, the company emphasizes opportunities in North America, Europe, and the Asia Pacific region. For publicly traded companies, HBM generally prioritizes those that originated within its private investment portfolio. The firm often increases its commitment to portfolio companies through subsequent financing rounds or after their initial public offering. HBM frequently secures a seat on the portfolio company's Board of Directors and may acquire majority stakes. While primarily investing through equity, it also employs various other financial instruments, including convertible bonds, debt securities, structured products, and derivatives. Exits from these investments are typically facilitated through trade sales or initial public offerings.

Company Valuation

Fairly valued
4/7

Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. In particular, the stock is underpriced on P/E, of fair value

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Slightly negative
3/7

The average target price of HBMN.SW is 280 and suggests 12.2% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendat

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

13.07.2026 14:37

Shares of L’Oréal’s small-cap partner have surged. It will go private

13.07.2026 13:45

SK Hynix Shares Have Their Worst Day Ever After a Record-Breaking U.S. Debut. Is It Time to Buy?

13.07.2026 13:09

Meta shut down its new AI photo-generation feature less than a week after its launch

13.07.2026 11:45

Wall Street's New Leaders: Who Will Succeed Buffett and Dalio?

13.07.2026 11:04

Oil prices approached $80 per barrel amid renewed tensions between the U.S. and Iran

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026